Elucidating the impact of bacterial lipases, human serum albumin, and FASII inhibition on the utilization of exogenous fatty acids by Staphylococcus aureus

mSphere. 2023 Dec 20;8(6):e0036823. doi: 10.1128/msphere.00368-23. Epub 2023 Nov 28.

Abstract

Incorporation of host-derived exogenous fatty acids (eFAs), particularly unsaturated fatty acids (UFAs), by Staphylococcus aureus could affect the bacterial membrane fluidity and susceptibility to antimicrobials. In this work, we found that glycerol ester hydrolase (Geh) is the primary lipase hydrolyzing cholesteryl esters and, to a lesser extent, triglycerides and that human serum albumin (HSA) could serve as a buffer of eFAs, where low levels of HSA facilitate the utilization of eFAs but high levels of HSA inhibit it. The fact that the type II fatty acid synthesis (FASII) inhibitor, AFN-1252, leads to an increase in UFA content even in the absence of eFA suggests that membrane property modulation is part of its mechanism of action. Thus, Geh and/or the FASII system look to be promising targets to enhance S. aureus killing in a host environment by restricting eFA utilization or modulating membrane properties, respectively.

Keywords: AFN-1252; Staphylococcus aureus; bacterial lipase; exogenous fatty acid; human serum albumin; lipidomics.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Fatty Acids* / metabolism
  • Humans
  • Lipase / metabolism
  • Serum Albumin, Human / metabolism
  • Staphylococcus aureus* / metabolism

Substances

  • Fatty Acids
  • Serum Albumin, Human
  • Lipase
  • Anti-Bacterial Agents